NH TherAguix Continues Phase II NANOBRAINMETS Trial for Brain Metastases Post-Futility Analysis

NH TherAguix (NHT), a biotechnology firm in Phase II clinical trials, focuses on developing advanced nanomedicine for precision radiotherapy in cancer treatment. Recently, the Data and Safety Monitoring Board (DSMB) gave the green light to continue NANOBRAINMETS, a Phase II trial managed by the Dana Farber Cancer Institute, following a scheduled futility analysis after 50% of patient enrollment and follow-up.

The ongoing assessment of the study has not identified any severe adverse reactions related to AGuIX® administration, emphasizing its favorable safety profile. AGuIX®, developed by NHT, is aimed at enhancing tumor targeting and amplifying radiobiological damage specifically to tumor tissues.

To date, 96 patients have been randomized out of the 134 planned for the study's protocol. The next interim analysis, expected by late 2024, will evaluate the clinical efficacy of AGuIX®.

NH TherAguix is in Phase II of clinical development, creating AGuIX®, a nano drug intended to treat tumors and metastases in patients receiving radiotherapy. Radiotherapy is administered to about 60% of cancer patients. AGuIX®’s pharmacological properties and its bio-distribution mechanism enhance radiotherapy precision and efficacy within tumors, showcasing its potential for a broad range of cancers.

AGuIX® is currently under evaluation in multiple Phase II randomized trials for different cancer types, including brain metastases, glioblastoma, pancreatic cancer, and lung cancer. Over 200 patients have been treated with AGuIX®, showing an excellent safety profile and promising preliminary clinical results.

AGuIX® is protected by 18 patent families and has undergone extensive testing in various preclinical models. Its results have been documented in more than 80 high-impact, peer-reviewed scientific publications.